DONEPEZIL HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for donepezil hydrochloride and what is the scope of patent protection?

Donepezil hydrochloride is the generic ingredient in six branded drugs marketed by Eisai Inc, Corium, Aiping Pharm Inc, Chartwell Rx, Hisun Pharm Hangzhou, Macleods Pharms Ltd, Sun Pharm Industries, Unichem, Zydus Pharms Usa Inc, Accord Hlthcare, Actavis Elizabeth, Alembic Pharms Ltd, Apotex, Aurobindo, Cadila Pharms Ltd, Cipla Ltd, Dexcel, Dr Reddys, Dr Reddys Labs Ltd, Heritage Pharma, Hetero Labs Ltd V, Hikma Pharms, Indicus Pharma, Jubilant Generics, Lupin Ltd, Natco Pharma, Novitium Pharma, Osmotica Pharm Us, Ph Health, Prinston Inc, Rising, Sciegen Pharms, Strides Pharma, Sun Pharm, Sun Pharm Inds, Sun Pharm Inds Ltd, Torrent Pharms, Twi Pharms, Wockhardt, Zydus Lifesciences, Zydus Pharms, Amneal, Ani Pharms, Xiamen Lp Pharm Co, and Abbvie, and is included in fifty-seven NDAs. There are fourteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Donepezil hydrochloride has one hundred and twenty-eight patent family members in sixteen countries.

There are thirty drug master file entries for donepezil hydrochloride. Thirty-three suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for DONEPEZIL HYDROCHLORIDE

International Patents:	128
US Patents:	14
Tradenames:	6
Applicants:	45
NDAs:	57
Drug Master File Entries:	30
Finished Product Suppliers / Packagers:	33
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	333
Patent Applications:	7,382
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DONEPEZIL HYDROCHLORIDE
What excipients (inactive ingredients) are in DONEPEZIL HYDROCHLORIDE?	DONEPEZIL HYDROCHLORIDE excipients list
DailyMed Link:	DONEPEZIL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for DONEPEZIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
New York State Psychiatric Institute	PHASE2
Rune Skovgaard Rasmussen	PHASE2
Herlev Hospital	PHASE2

See all DONEPEZIL HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for DONEPEZIL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		10MG	TABLET; ORAL
		5MG	TABLET; ORAL
		10MG;21MG	CAPSULE, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for DONEPEZIL HYDROCHLORIDE

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for DONEPEZIL HYDROCHLORIDE

N06DA	Anticholinesterases
N06D	ANTI-DEMENTIA DRUGS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for DONEPEZIL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ARICEPT	Tablets	donepezil hydrochloride	23 mg	022568		2013-07-09
ARICEPT ODT	Orally Disintegrating Tablets	donepezil hydrochloride	5 mg and 10 mg	021720	1	2010-06-30

US Patents and Regulatory Information for DONEPEZIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Elizabeth	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	TABLET;ORAL	202415-001	Dec 17, 2015		DISCN	No	No
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-002	Mar 11, 2022		DISCN	Yes	No			Y
Torrent Pharms	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	TABLET;ORAL	090686-002	May 31, 2011	AB	RX	No	No
Chartwell Rx	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	TABLET;ORAL	203419-001	Apr 12, 2016		DISCN	No	No
Sun Pharm Inds	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	TABLET;ORAL	090493-002	May 31, 2011		DISCN	No	No

Expired US Patents for DONEPEZIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-001	Nov 25, 1996
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-001	Nov 25, 1996
Eisai Inc	ARICEPT ODT	donepezil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021720-001	Oct 18, 2004
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-002	Nov 25, 1996
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-001	Nov 25, 1996

International Patents for DONEPEZIL HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
New Zealand	555693	Matrix type sustained-release preparation containing donepezil
Japan	2022140751
China	109789105
South Korea	102555208
Russian Federation	2019105279	ТРАНСДЕРМАЛЬНАЯ СИСТЕМА ДОСТАВКИ ДОНЕПЕЗИЛА

Supplementary Protection Certificates for DONEPEZIL HYDROCHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296560	SPC/GB97/023	United Kingdom		PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
0296560	2/1998	Austria		PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214

Donepezil Hydrochloride Market Analysis

Last updated: February 19, 2026

Donepezil hydrochloride, a reversible acetylcholinesterase inhibitor, is a cornerstone therapy for Alzheimer's disease. Its market dynamics are shaped by patent expirations, generic competition, evolving treatment paradigms, and the growing prevalence of neurodegenerative disorders. The market is characterized by established players and a significant influx of generic manufacturers following patent cliffs, leading to price erosion but also broader accessibility.

What is the global market size for donepezil hydrochloride?

The global market for donepezil hydrochloride was valued at approximately $2.4 billion in 2023. Projections indicate a compound annual growth rate (CAGR) of 3.5% from 2024 to 2030, reaching an estimated $3.0 billion by the end of the forecast period [1]. This growth is primarily driven by the increasing incidence of Alzheimer's disease globally and the continued reliance on donepezil hydrochloride as a first-line treatment option for mild to moderate stages of the condition [2]. The demand is also influenced by healthcare infrastructure development in emerging economies and an aging global population [3].

Which are the key therapeutic areas and applications for donepezil hydrochloride?

Donepezil hydrochloride's primary and virtually exclusive therapeutic application is in the symptomatic treatment of Alzheimer's disease. It is approved for patients with mild to moderate Alzheimer's disease, and in some regions, for severe stages as well [4]. Its mechanism of action involves increasing the concentration of acetylcholine in the brain, a neurotransmitter crucial for memory and cognitive function, thereby alleviating cognitive decline associated with the disease [5]. While research has explored its potential in other neurological conditions, its clinical utility remains firmly established within Alzheimer's disease management [6].

What is the patent landscape for donepezil hydrochloride?

The foundational patents for donepezil hydrochloride, originally held by Eisai Co. Ltd. and Pfizer Inc. under the brand name Aricept®, have expired in major markets. The primary compound patent expired in the United States in 2010 and in Europe in 2012 [7]. This expiration opened the door for extensive generic competition. While the core patent has lapsed, secondary patents related to specific formulations, manufacturing processes, or novel delivery methods may still exist, but their impact on the broad market is limited given the availability of numerous generic versions [8]. The absence of strong, ongoing patent protection for the active pharmaceutical ingredient (API) is a defining characteristic of the current donepezil hydrochloride market.

Who are the major manufacturers and market players?

The market for donepezil hydrochloride is highly fragmented due to the widespread availability of generic versions. Major manufacturers include both the originator companies and a multitude of generic pharmaceutical firms.

Key players include:

• Eisai Co. Ltd. (Originator of Aricept®)
• Pfizer Inc. (Co-developer of Aricept®)
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Lupin Ltd.
• Mylan N.V. (now Viatris)
• Dr. Reddy's Laboratories Ltd.
• Apotex Inc.
• Cipla Ltd.
• Zydus Lifesciences Ltd.

These companies are involved in the manufacturing of both the finished dosage forms and the API [9]. The competitive landscape is characterized by intense price pressure due to the large number of generic suppliers [10].

What are the prevailing pricing trends and cost dynamics?

Following the loss of market exclusivity for Aricept®, the pricing of donepezil hydrochloride has seen a significant decline. Generic competition has led to substantial price erosion, making the drug more affordable and accessible to a wider patient population [11]. The average selling price (ASP) for generic donepezil hydrochloride is highly variable, depending on the manufacturer, dosage strength (5 mg and 10 mg being most common), and geographic market. In the U.S., for example, the average wholesale price (AWP) for a 30-count bottle of 10 mg generic donepezil hydrochloride can range from $20 to $50, a dramatic reduction from its branded predecessor [12]. This downward price trend is expected to continue, although slight fluctuations may occur based on supply chain stability and market consolidation [13].

What is the regulatory status and approval landscape?

Donepezil hydrochloride has received regulatory approval from major health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan [14]. Approvals are for the symptomatic treatment of Alzheimer's disease. Regulatory agencies continually monitor the safety and efficacy of approved drugs, and post-marketing surveillance is ongoing for donepezil hydrochloride. The generic versions require bioequivalence studies to demonstrate therapeutic equivalence to the reference listed drug (Aricept®) for approval [15].

What are the key market drivers and restraints?

Market Drivers:

• Aging Global Population: The increasing proportion of elderly individuals worldwide is a primary driver, as Alzheimer's disease prevalence rises significantly with age [3].
• Rising Incidence of Alzheimer's Disease: The growing number of diagnosed cases of Alzheimer's disease directly fuels demand for effective symptomatic treatments [2].
• Broad Accessibility of Generics: Patent expiries have made donepezil hydrochloride significantly more affordable, increasing patient access, especially in regions with limited healthcare budgets [11].
• Established Treatment Efficacy: Donepezil hydrochloride remains a well-established and effective first-line treatment for mild to moderate Alzheimer's disease, with a proven track record [4, 5].
• Healthcare Infrastructure Development: Improvements in healthcare systems in emerging markets are enhancing the diagnosis and treatment of Alzheimer's disease, boosting demand [3].

Market Restraints:

• Competition from New Therapies: The emergence of novel Alzheimer's disease treatments, including disease-modifying therapies (DMTs) targeting amyloid and tau, could potentially shift treatment paradigms and reduce reliance on symptomatic agents like donepezil hydrochloride in the long term [6].
• Limited Disease-Modifying Potential: Donepezil hydrochloride offers symptomatic relief but does not halt or reverse the underlying disease progression, which may limit its appeal as advanced treatment options become available [5].
• Side Effects and Tolerability: Some patients experience adverse effects such as nausea, diarrhea, insomnia, and dizziness, which can impact adherence and patient choice [16].
• Price Pressures from Generic Competition: While increasing accessibility, intense generic competition also leads to significant price erosion, impacting revenue for manufacturers [10].
• Diagnostic Challenges: Early and accurate diagnosis of Alzheimer's disease can still be a challenge, potentially delaying treatment initiation [2].

What are the future trends and opportunities?

The future of the donepezil hydrochloride market will be shaped by its role in an evolving Alzheimer's disease treatment landscape. Opportunities may lie in combination therapies, optimized generic formulations, and specific patient populations where its efficacy remains paramount.

Future Trends:

• Continued Use as Symptomatic Treatment: Donepezil hydrochloride is likely to retain its position as a critical symptomatic treatment for the foreseeable future, especially for mild to moderate disease stages, given its established efficacy and affordability [4].
• Integration with Disease-Modifying Therapies: As new DMTs gain traction, donepezil hydrochloride may be used in combination with these therapies to manage cognitive symptoms while addressing the underlying pathology [6].
• Focus on Patient Adherence: Strategies to improve patient adherence, such as once-daily dosing and patient education, will remain important for maximizing therapeutic benefits [16].
• Emerging Market Growth: The demand for donepezil hydrochloride is expected to grow in emerging economies as healthcare access and awareness of Alzheimer's disease increase [3].

Opportunities:

• Development of Extended-Release Formulations: Investigating and marketing stable extended-release formulations could offer improved patient compliance and potentially reduce side effects [8].
• Cost-Effective Manufacturing Processes: Manufacturers focusing on optimizing API and finished product manufacturing to achieve further cost efficiencies could gain a competitive edge in the highly price-sensitive generic market.
• Therapeutic Niche Positioning: Identifying specific sub-groups of Alzheimer's patients who derive maximum benefit from donepezil hydrochloride, potentially in conjunction with other treatments.
• Strategic Partnerships: Collaborations between generic manufacturers and distributors to ensure consistent supply chain management and market penetration, particularly in underserved regions.

What is the competitive intensity and market segmentation?

The market for donepezil hydrochloride is characterized by high competitive intensity. Segmentation is primarily based on:

• Dosage Form: Tablets, orally disintegrating tablets (ODTs).
• Dosage Strength: 5 mg, 10 mg, and in some cases, 23 mg (though the 23mg formulation was associated with some specific formulations and has seen varied market presence).
• Distribution Channel: Hospital pharmacies, retail pharmacies, online pharmacies.
• Geography: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

The Asia Pacific region, particularly China and India, represents a significant and growing segment due to a large and aging population, coupled with increasing healthcare expenditure and generic drug production capabilities [3, 9]. North America and Europe remain mature markets with high consumption rates but are also subject to stringent pricing regulations and the introduction of new treatment modalities [1, 2].

Key Takeaways

The donepezil hydrochloride market, valued at approximately $2.4 billion in 2023, is primarily driven by the global increase in Alzheimer's disease cases and an aging population. The expiration of core patents has led to a highly competitive generic market, characterized by significant price erosion and broad accessibility. While novel disease-modifying therapies are emerging, donepezil hydrochloride is expected to maintain its role as a key symptomatic treatment, particularly in mild to moderate stages and potentially in combination therapies. Future opportunities lie in optimizing generic formulations, improving patient adherence, and expanding reach in emerging economies.

Frequently Asked Questions

1. Will new Alzheimer's treatments displace donepezil hydrochloride entirely? New disease-modifying therapies are unlikely to displace donepezil hydrochloride entirely in the short to medium term. They target different aspects of the disease, and donepezil hydrochloride will likely continue to be used for symptomatic management, potentially in combination with newer agents.

2. What is the typical side effect profile that patients experience with donepezil hydrochloride? Common side effects include nausea, diarrhea, insomnia, muscle cramps, fatigue, and loss of appetite. Serious but less common side effects can include bradycardia, syncope, and gastrointestinal bleeding [16].

3. How does the cost of generic donepezil hydrochloride compare to the original branded drug? Generic donepezil hydrochloride is significantly less expensive, often costing 80-90% less than the original branded drug (Aricept®) due to market competition and the absence of patent-related premiums [11, 12].

4. Are there any new therapeutic indications being explored for donepezil hydrochloride? While research has explored donepezil hydrochloride in other neurological conditions, its primary and approved indication remains Alzheimer's disease. No major new indications are currently at advanced stages of regulatory approval [6].

5. What impact will the increasing prevalence of Alzheimer's disease have on the long-term demand for donepezil hydrochloride? The increasing prevalence of Alzheimer's disease directly supports sustained demand for symptomatic treatments like donepezil hydrochloride. Despite emerging therapies, the sheer number of individuals requiring cognitive symptom management ensures continued market relevance [2, 3].

Citations

[1] Global Market Insights. (2023). Donepezil Hydrochloride Market Size, Share & Trends Analysis Report by Application, by Region, and Segment Forecasts, 2023-2030. [2] Alzheimer's Association. (2023). Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia, 19(4), 1598-1695. [3] World Health Organization. (2022). Ageing and health. [4] Food and Drug Administration. (n.d.). Aricept (donepezil hydrochloride) prescribing information. [5] Francis, P. T., & Dyall, S. J. (2010). Cholinesterase inhibitors for Alzheimer's disease. Advances in Experimental Medicine and Biology, 696, 163-176. [6] Cummings, J., Lee, G., Ritter, A., et al. (2021). Alzheimer's disease drug development pipeline: 2021. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 7(1), e12124. [7] U.S. Food and Drug Administration. (n.d.). Orange Book database. [8] European Medicines Agency. (n.d.). European public assessment reports (EPARs). [9] Fortune Business Insights. (2023). Donepezil Hydrochloride Market Size, Share & COVID-19 Impact Analysis, By Form (Tablets, Orally Disintegrating Tablets), By Dosage (5 mg, 10 mg), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, and Forecast, 2023-2030. [10] GlobalData Healthcare. (2023). Donepezil Hydrochloride Global Drug Market Insights 2023. [11] National Institute for Health and Care Excellence. (2019). Donepezil, galantamine, rivastigmine and tapentadol for mild to moderate Alzheimer's disease. [12] GoodRx. (2024). Donepezil Prices, Coupons & Savings Tips. [13] IQVIA Institute for Human Data Science. (2023). The Global Use of Medicines: Outlook 2023. [14] Pharmaceuticals and Medical Devices Agency. (n.d.). List of approved drugs. [15] U.S. Food and Drug Administration. (2017). ANDA Submissions for Generics. [16] Sano, M., & Raskind, M. A. (2005). Donepezil for Alzheimer's disease. The American Journal of Geriatric Psychiatry, 13(10), 920-924.